Currently out of the existing stock ratings of Uy Ear, 19 are a HOLD (28.79%), 47 are a BUY (71.21%).

Uy Ear

Work Performance Price Targets & Ratings Chart

Analyst Uy Ear, currently employed at MIZUHO, carries an average stock price target met ratio of 30.95% that have a potential upside of 15.85% achieved within 57 days.

Uy Ear’s has documented 123 price targets and ratings displayed on 10 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 17-May-2024.

Wall Street Analyst Uy Ear

Analyst best performing recommendations are on NBIX (NEUROCRINE BIOSCIENCES).
The best stock recommendation documented was for ARQT (ARCUTIS BIOTHERAPEUTICS ) at 1/2/2024. The price target of $8 was fulfilled within 45 days with a profit of $4.57 (133.24%) receiving and performance score of 29.61.

Average potential price target upside

ARQT Arcutis Biotherapeutics  AVRO AVROBIO NBIX Neurocrine Biosciences ACAD ACADIA Pharmaceuticals ALKS Alkermes Plc EOLS Evolus OCGN Ocugen SELB Selecta Biosciences SRPT Sarepta Therapeutics RVNC Revance The

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

18

$7.38 (69.49%)

18

5 days ago

1/12 (8.33%)

$8.19 (83.49%)

102

Buy

18

$7.38 (69.49%)

17

2 months ago

2/16 (12.5%)

$8.76 (94.81%)

58

Hold

11

$0.38 (3.58%)

6

4 months 17 days ago

2/4 (50%)

$0.59 (5.67%)

55

Buy

11

$0.38 (3.58%)

10

6 months 24 days ago

2/8 (25%)

$8.4 (323.08%)

89

Buy

10

$-0.62 (-5.84%)

45

8 months 2 days ago

1/3 (33.33%)

$7.89 (373.93%)

106

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Uy Ear is most bullish on?

Potential upside of $26.89 has been obtained for SRPT (SAREPTA THERAPEUTICS)

Which stock is Uy Ear is most reserved on?

Potential downside of -$7.43 has been obtained for NBIX (NEUROCRINE BIOSCIENCES)

What Year was the first public recommendation made by Uy Ear?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?